Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic
Latigo Biotherapeutics Raises $150M for Non-Opioid Pain Drug Development
Latigo Biotherapeutics has secured a $150 million Series B funding round led by Blue Owl Capital14.
The funds will be used to advance Latigo's pipeline of non-opioid pain management drugs, particularly its Nav1.8 inhibitors LTG-001 and LTG-30514.
LTG-001, Latigo's lead candidate for acute pain, is currently in Phase 1 trials and has received FDA Fast Track designation15.
LTG-305, targeting chronic pain, is also undergoing Phase 1 trials14.
The company aims to provide effective, rapid-acting pain relief without the risk of addiction associated with opioids25.
Latigo's funding comes amid increased interest in non-opioid pain treatments, following Vertex Pharmaceuticals' recent FDA approval for Journavx (suzetrigine)1.
The financing round included participation from investors such as Deep Track Capital, Access Biotechnology, Qatar Investment Authority, and Sanofi Ventures1.
Latigo's pipeline also includes preclinical candidates targeting Nav1.8 and acid-sensing ion channels1.
The company's approach focuses on targeting pain at its source by inhibiting peripheral sensory neurons responsible for pain signaling45.
This significant funding reflects the urgent need for non-opioid pain treatments in the context of the ongoing opioid crisis, with 8.6 million Americans reporting misuse of prescription opioids in 20231.
Sources:
1. https://www.fiercebiotech.com/biotech/latigo-saddles-150m-series-b-move-non-opioid-pain-drugs-through-clinic
4. https://www.pharmaceutical-technology.com/news/latigo-non-opioid-pain-treatment/
5. https://www.prnewswire.com/news-releases/latigo-biotherapeutics-granted-fda-fast-track-designation-for-ltg-001--potential-best-in-class-nav1-8-inhibitor-for-the-non-opioid-treatment-of-acute-pain-302387994.html